[go: up one dir, main page]

EP0602181A1 - Medicinal aerosol formulations - Google Patents

Medicinal aerosol formulations

Info

Publication number
EP0602181A1
EP0602181A1 EP92920106A EP92920106A EP0602181A1 EP 0602181 A1 EP0602181 A1 EP 0602181A1 EP 92920106 A EP92920106 A EP 92920106A EP 92920106 A EP92920106 A EP 92920106A EP 0602181 A1 EP0602181 A1 EP 0602181A1
Authority
EP
European Patent Office
Prior art keywords
formulation according
drug
propellant
glycerol phosphatide
glycerol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92920106A
Other languages
German (de)
French (fr)
Inventor
Martin J. 51 Pinfold Gate Oliver
Philip A. 91 Rockhill Drive Jinks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Publication of EP0602181A1 publication Critical patent/EP0602181A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant

Definitions

  • This invention relates to medicinal aerosol formulations and in particular to formulations suitable for pulmonary, nasal, buccal, or topical administration which are at least substantially free of chlorofluorocarbons.
  • inhalation Since the metered dose pressurized inhaler was introduced in the mid 1950's, inhalation has become the most widely used route for delivering bronchodilator drugs and steroids to the airways of asthmatic patients. Compared with oral administration of bronchodilators, inhalation offers a rapid onset of action and a low instance of systemic side effects. More recently, inhalation from a pressurized inhaler has been a route selected for the administration of other drugs, e.g., ergotamine, which are not primarily concerned with treatment of a bronchial malady. The metered dose inhaler is dependent upon the propulsive force of a propellant system used in its manufacture.
  • the propellant generally comprises a mixture of liquified chlorofluorocarbons (CFC's) which are selected to provide the desired vapor pressure and stability of the formulation.
  • CFC's chlorofluorocarbons
  • Propellants 11, 12 and 114 are the most widely used propellants in aerosol formulations for inhalation administration.
  • the aerosol formulations are generally in the form of a suspension of drug in the propellant utilizing a surfactant.
  • a surfactant there are few drugs which are soluble in aerosol propellants and solution formulations have been prepared using a polar cosolvent, such as ethanol.
  • European Patent No. 209547 discloses solution formulations of drugs in chlorofluorocarbon propellants in the presence of a glycerol phosphatide.
  • Patent Application No. 89312270.5 discloses that 1,1,1,2- tetrafluoroethane (Propellant 134a) , may be employed as a propellant for aerosol formulations suitable for inhalation therapy when used in combination with a compound (hereinafter an "adjuvant") having a higher polarity than Propellant 134a.
  • the adjuvant should be miscible with Propellant 134a in the amounts employed.
  • Suitable adjuvants include alcohols such as ethyl alcohol, isopropyl alcohol, propylene glycol, hydrocarbons such as propane, butane, isobutane, pentane, isopentane, neopentane, and other propellants such as those commonly referred to as Propellants 11, 12, 114, 113, 142b, 152a 124, and dimethyl ether.
  • Preferred adjuvants are liquids or gases at room temperature (22°C) at atmospheric pressure. The combination of one or more of such adjuvants with
  • Propellant 134a provides a propellant system which has comparable properties to those of propellant systems based on CFC's, allowing use of known surfactants and additives in the pharmaceutical formulations. This is particularly advantageous since the toxicity and use of such compounds in metered dose inhalers for drug delivery to the human lung is well established.
  • hydrocarbons such as n-butane, isobutane, and propane be considered as CFC replacements in aerosol formulations.
  • hydrocarbons have low densities relative to the drugs in the formulations and that suspension formulations sediment rapidly and are unacceptable.
  • solubility of many drugs in these hydrocarbons is not sufficient, and solution formulations therefore do not contain suitable amounts of drug.
  • an aerosol formulation which contains no dispersed phase, comprising: an aerosol propellant system comprising a propellant selected from n-butane, dimethylether, and mixtures thereof; a glycerol phosphatide; and a drug, in which the drug is dissolved in the composition in an amount greater than could be achieved in the absence of glycerol phosphatide.
  • the glycerol phosphatide may be any one of the following compounds; phosphatidylcholine (lecithin) , phosphatidylethanolamine (cephalin) , phosphatidyl- inositol, phosphatidylserine, diphosphatidylglycerol, or phosphatidic acid.
  • compositions of the invention appear visibly to be true solutions since there is no dispersed phase apparent, they are more correctly referred to as micellar solutions.
  • the formulations of the invention can be prepared by forming a concentrate of glycerol phosphatide with a drug and propellant.
  • the concentrate can be formed by simple admixture with agitation and optionally under heating, e.g., 50 ⁇ C, until complete dissolution of the drug has been attained.
  • the concentrate can then be mixed with the remainder of the propellant formulation.
  • Phosphatidylcholine is the most suitable glycerol phosphatide to use in view of its low toxicity and high drug solubilizing efficacy.
  • Commercial grades of lecithin vary widely in phosphatidylcholine content.
  • Purified phosphatidylcholine (e.g., having phosphatidylcholine content in excess of about 90% by weight) is preferred for use in this invention.
  • Phosphatidylcholine purified from soya bean lecithin is readily available commercially and suitable grades include EpikuronTM 200 (Lucas-Meyer) and LipoidTM S100 (Lipoid KG) . Both products have a phosphatidylcholine content in excess of 95%.
  • Suitable drugs for use in the invention include those which exhibit at least a very slight solubility in the propellant system.
  • the drug will be in a relatively non-polar form, e.g., the form of an ester, base, or free alcohol.
  • Highly polar ionic salts of drugs are generally less suitable since it is difficult to solubilize the drug in sufficient quantity even with the presence of a small amount of cosolvent.
  • the drug is generally present in the formulation in an amount in the range from 0.1 to 15 mg/mL, usually from 2 to 10 mg/mL based on the total volume of the formulation.
  • Suitable medicaments include those disclosed in European Patent Application No.
  • 89312270.5 and include, but are not limited to, albuterol, beclomethasone dipropionate, fentanyl citrate, isoprenaline, rimiterol, pirbuterol, adrenaline, disodium cromoglycate (DSCG) , histamine acid sulphate, morphine and its salts, ergotamine, atropine, captopril, propranolol, diazepam, glycerol trinitrate. isosorbide dinitrate, isosorbide mononitrate, and ipratropium bromide.
  • albuterol beclomethasone dipropionate
  • fentanyl citrate include, but are not limited to, albuterol, beclomethasone dipropionate, fentanyl citrate, isoprenaline, rimiterol, pirbuterol, adrenaline, disodium cromoglycate (DSCG) , histamine acid sulphate, morphine
  • the propellant system contains one or both of n- butane and dimethylether and can include copropellants such as isobutane and propane.
  • the propellant system may include minor amounts of other propellants, but preferably contains no more than 5% by weight of CFCs. More preferably the propellant system is free from CFCs.
  • the compositions comprising drug, glycerol phosphatide, and propellant system contain one to 500, preferably one to 30, more preferably 2 to 10, parts by weight drug based on 100 parts by weight glycerol phosphatide, and 0.01 to 20, preferably 0.01 to 10, more preferably 0.01 to 3, parts by weight glycerol phosphatide based on 100 parts by weight propellant system.
  • a concentrate was prepared by combining the drug, the phosphatidylcholine, and a portion of the n-butane in a pressure resistant vessel. Dissolution of this concentrate was achieved by heating for 1 hour in a water bath maintained at 55°C.
  • the solution was then cooled and the remainder of the n-butane was added.
  • the resulting formulation was in the form of a stable solution.
  • the drug, phosphatidylcholine, and n-butane were mixed in a pressure resistant vessel to form a concentrate. Dissolution was achieved by heating for 1 hour in a water bath maintained at 55°C.
  • the solution was then cooled and the dimethylether was added.
  • the resulting formulation was in the form of a stable solution.
  • the drug, phosphatidylcholine, and a portion of the dimethylether were mixed in a pressure resistant vessel to form a concentrate. Dissolution was achieved by agitation at room temperature.
  • the solution was then cooled to -40°C followed by addition of the other components of the propellant system.
  • the resulting formulation was in the form of a stable solution.
  • the components were introduced into a polyethyleneterephthalate vial (15 mL) and a non- metering valve was crimped in place. An n-butane overage of 0.300 g was present in the formulation to allow for evaporation in the head space in the vial. A solution was obtained after three hours immersion in a 55°C water bath. The formulation was allowed to stand and cool to room temperature. No precipitation or crystallization was observed.
  • the formulation was prepared as in Example 5.
  • EXAMPLE 7 The following materials were weighed into a polyethyleneterephthalate vial and a non-metering valve was crimped in place: lal
  • LipoidTM S100 phosphatidylcholine 0.700 n-Butane 5.600
  • the drug (atropine in Example 8 and captopril in Example 9) and the phosphatidylcholine were weighed into a plastic coated glass bottle which was then sealed with a non-metering valve. The required quantity of n-butane was then pressure-filled into the sealed bottle to form a concentrate. The sealed bottle was then heated for 1 hour at 55°C in a water bath. The sealed bottle was then allowed to cool to room temperature and the remaining propellants were filled into the bottle.
  • EXAMPLE 8 The drug, atropine (base) , was solubilized within 1 hour in the concentrate and remained in solution when the remaining propellants were added.
  • EXAMPLE 9 The drug, captopril, was solubilized within one hour in the concentrate and remained in solution when the remaining propellants were added.
  • EXAMPLES 10 AND 11 The following formulations were prepared:
  • the formulations were prepared by weighing the drug (propranolol hydrochloride in Example 10 and diazepam in Example 11) , the phosphatidylcholine, and the ethanol into a glass vial, sealing the vial with a non-metering valve and pressure filling the required amount of n-butane into the sealed vial to form a concentrate. Each vial was then heated at 55°C for 2 hours in a water bath. The vials were allowed to cool to room temperature and the remaining propellants were filled into the vials.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composition d'aérosol en solution contenant un médicament, un phosphatide de glycérol, et un système propulsif contenant du n-butane, du diméthyléther ou un mélange de ceux-ci.A solution aerosol composition containing a drug, a glycerol phosphatide, and a propellant system containing n-butane, dimethyl ether or a mixture thereof.

Description

MEDICINAL AEROSOL FORMULATIONS
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to medicinal aerosol formulations and in particular to formulations suitable for pulmonary, nasal, buccal, or topical administration which are at least substantially free of chlorofluorocarbons.
Description of the Related Art
Since the metered dose pressurized inhaler was introduced in the mid 1950's, inhalation has become the most widely used route for delivering bronchodilator drugs and steroids to the airways of asthmatic patients. Compared with oral administration of bronchodilators, inhalation offers a rapid onset of action and a low instance of systemic side effects. More recently, inhalation from a pressurized inhaler has been a route selected for the administration of other drugs, e.g., ergotamine, which are not primarily concerned with treatment of a bronchial malady. The metered dose inhaler is dependent upon the propulsive force of a propellant system used in its manufacture. The propellant generally comprises a mixture of liquified chlorofluorocarbons (CFC's) which are selected to provide the desired vapor pressure and stability of the formulation. Propellants 11, 12 and 114 are the most widely used propellants in aerosol formulations for inhalation administration.
The aerosol formulations are generally in the form of a suspension of drug in the propellant utilizing a surfactant. There are few drugs which are soluble in aerosol propellants and solution formulations have been prepared using a polar cosolvent, such as ethanol. European Patent No. 209547 discloses solution formulations of drugs in chlorofluorocarbon propellants in the presence of a glycerol phosphatide.
In recent years it has been established that CFC's react with the ozone layer around the earth and contribute towards its depletion. There has been considerable pressure around the world to reduce substantially the use of CFC's, and various Governments have banned the "non-essential" use of CFC's. Such "non-essential" uses include the use of CFC's as refrigerants and blowing agents, but heretofore the use of CFC's in medicines, which contributes to less than 1% of the total use of CFC's, has not been restricted. Nevertheless, in view of the adverse effect of CFC's on the ozone layer it is desirable to seek alternative propellant systems which are suitable for use in inhalation aerosols.
Various alternative propellants have been suggested for use in place of CFC's. European Patent Application No. 89312270.5 discloses that 1,1,1,2- tetrafluoroethane (Propellant 134a) , may be employed as a propellant for aerosol formulations suitable for inhalation therapy when used in combination with a compound (hereinafter an "adjuvant") having a higher polarity than Propellant 134a. The adjuvant should be miscible with Propellant 134a in the amounts employed. Suitable adjuvants include alcohols such as ethyl alcohol, isopropyl alcohol, propylene glycol, hydrocarbons such as propane, butane, isobutane, pentane, isopentane, neopentane, and other propellants such as those commonly referred to as Propellants 11, 12, 114, 113, 142b, 152a 124, and dimethyl ether. Preferred adjuvants are liquids or gases at room temperature (22°C) at atmospheric pressure. The combination of one or more of such adjuvants with
Propellant 134a provides a propellant system which has comparable properties to those of propellant systems based on CFC's, allowing use of known surfactants and additives in the pharmaceutical formulations. This is particularly advantageous since the toxicity and use of such compounds in metered dose inhalers for drug delivery to the human lung is well established.
It has been suggested that hydrocarbons, such as n-butane, isobutane, and propane be considered as CFC replacements in aerosol formulations. However, it has been found that such hydrocarbons have low densities relative to the drugs in the formulations and that suspension formulations sediment rapidly and are unacceptable. Furthermore, the solubility of many drugs in these hydrocarbons is not sufficient, and solution formulations therefore do not contain suitable amounts of drug.
Summary of the Invention
It has now been found that the solubility of many drugs in certain hydrocarbons and dimethyl ether may be enhanced in the presence of glycerol phosphatide.
Therefore according to the present invention there is provided an aerosol formulation which contains no dispersed phase, comprising: an aerosol propellant system comprising a propellant selected from n-butane, dimethylether, and mixtures thereof; a glycerol phosphatide; and a drug, in which the drug is dissolved in the composition in an amount greater than could be achieved in the absence of glycerol phosphatide.
Detailed Description of the Invention
The glycerol phosphatide may be any one of the following compounds; phosphatidylcholine (lecithin) , phosphatidylethanolamine (cephalin) , phosphatidyl- inositol, phosphatidylserine, diphosphatidylglycerol, or phosphatidic acid.
It has been found that drugs having at least very slight solubility in hydrocarbon propellants will exhibit an enhanced solubility in the propellant in the presence of glycerol phosphatide. Surprisingly it has been found that glycerol phosphatides cause complete dissolution of certain drugs in n-butane and di ethylether. It is postulated that this enhanced solubility is attributable to drug in true solution becoming associated with reverse micelles of the glycerol phosphatide which allows further drug to dissolve in the propellant. Thus, the solubilization process is believed to be as follows:
drug. drug in solution drug associated in propellant with reverse micelles of glycerol phosphatide
"Initial "Micellar solubilization" solubilization"
While the compositions of the invention appear visibly to be true solutions since there is no dispersed phase apparent, they are more correctly referred to as micellar solutions. The formulations of the invention can be prepared by forming a concentrate of glycerol phosphatide with a drug and propellant. The concentrate can be formed by simple admixture with agitation and optionally under heating, e.g., 50βC, until complete dissolution of the drug has been attained. The concentrate can then be mixed with the remainder of the propellant formulation. Phosphatidylcholine is the most suitable glycerol phosphatide to use in view of its low toxicity and high drug solubilizing efficacy. Commercial grades of lecithin vary widely in phosphatidylcholine content. Purified phosphatidylcholine (e.g., having phosphatidylcholine content in excess of about 90% by weight) is preferred for use in this invention. Phosphatidylcholine purified from soya bean lecithin is readily available commercially and suitable grades include Epikuron™ 200 (Lucas-Meyer) and Lipoid™ S100 (Lipoid KG) . Both products have a phosphatidylcholine content in excess of 95%.
It has been found that certain drugs which are practically insoluble in hydrocarbon propellants alone can be solubilized by adding a small amount, e.g., up to 5% by weight of a cosolvent, such as ethanol, to the formulation. It is postulated that the cosolvent enhances the initial solubilization step of the solubilization process. Certain commercially available forms of lecithin, e.g., Lipoid™ S45, contain ethanol in addition to their phosphatidylcholine content. With lecithins of this type, the ethanol may likewise enhance drug solubilization in a formulation of the invention.
Suitable drugs for use in the invention include those which exhibit at least a very slight solubility in the propellant system. In general, the drug will be in a relatively non-polar form, e.g., the form of an ester, base, or free alcohol. Highly polar ionic salts of drugs are generally less suitable since it is difficult to solubilize the drug in sufficient quantity even with the presence of a small amount of cosolvent. The drug is generally present in the formulation in an amount in the range from 0.1 to 15 mg/mL, usually from 2 to 10 mg/mL based on the total volume of the formulation. Suitable medicaments include those disclosed in European Patent Application No. 89312270.5 and include, but are not limited to, albuterol, beclomethasone dipropionate, fentanyl citrate, isoprenaline, rimiterol, pirbuterol, adrenaline, disodium cromoglycate (DSCG) , histamine acid sulphate, morphine and its salts, ergotamine, atropine, captopril, propranolol, diazepam, glycerol trinitrate. isosorbide dinitrate, isosorbide mononitrate, and ipratropium bromide.
The propellant system contains one or both of n- butane and dimethylether and can include copropellants such as isobutane and propane. The propellant system may include minor amounts of other propellants, but preferably contains no more than 5% by weight of CFCs. More preferably the propellant system is free from CFCs. In general, the compositions comprising drug, glycerol phosphatide, and propellant system contain one to 500, preferably one to 30, more preferably 2 to 10, parts by weight drug based on 100 parts by weight glycerol phosphatide, and 0.01 to 20, preferably 0.01 to 10, more preferably 0.01 to 3, parts by weight glycerol phosphatide based on 100 parts by weight propellant system.
The invention will now be illustrated by the following Examples.
EXAMPLE 1
A concentrate was prepared by combining the drug, the phosphatidylcholine, and a portion of the n-butane in a pressure resistant vessel. Dissolution of this concentrate was achieved by heating for 1 hour in a water bath maintained at 55°C.
The solution was then cooled and the remainder of the n-butane was added. The resulting formulation was in the form of a stable solution.
The drug, phosphatidylcholine, and n-butane were mixed in a pressure resistant vessel to form a concentrate. Dissolution was achieved by heating for 1 hour in a water bath maintained at 55°C.
The solution was then cooled and the dimethylether was added. The resulting formulation was in the form of a stable solution.
EXAMPLE 3
The formulation was prepared according to the general method of Example 2 and complete dissolution was achieved. EXAMPLE 4 mg/mL
Beclomethasone Dipropionate 1.00
Lipoid™ S100 phosphatidylcholine 7.00 n-Butane 114.92
Drivosol™ 32* 344.76
Dimethylether 114.92
582.60 *A mixture containing 77 percent isobutane, 4 percent n-butane, and 19 percent propane by weight.
The drug, phosphatidylcholine, and a portion of the dimethylether were mixed in a pressure resistant vessel to form a concentrate. Dissolution was achieved by agitation at room temperature.
The solution was then cooled to -40°C followed by addition of the other components of the propellant system. The resulting formulation was in the form of a stable solution.
EXAMPLE 5
131 Albuterol 0.007
Phosphatidylinosito1 0.050 ammonium salt n-Butane 0.400 n-Butane overage 0.300
0.757
The components were introduced into a polyethyleneterephthalate vial (15 mL) and a non- metering valve was crimped in place. An n-butane overage of 0.300 g was present in the formulation to allow for evaporation in the head space in the vial. A solution was obtained after three hours immersion in a 55°C water bath. The formulation was allowed to stand and cool to room temperature. No precipitation or crystallization was observed.
EXAMPLE 6
Isl
Albuterol 0.014
3-Sn-Phosphatidyl-L-Serine 0.100 n-Butane 0.700 n-Butane overage 0.300
1.114
The formulation was prepared as in Example 5.
After immersion in the waterbath for 2 hours a solution was obtained. The formulation was allowed to stand and cool to room temperature. No precipitation or crystallization was observed.
EXAMPLE 7 The following materials were weighed into a polyethyleneterephthalate vial and a non-metering valve was crimped in place: lal
Beta ethasone valerate 0.100
Lipoid™ S100 phosphatidylcholine 0.700 n-Butane 5.600
6.400
The vial was subjected to ultrasonic energy for 30 seconds and then placed in a water bath at 55°C. After 15 minutes solubilization had been achieved; upon cooling no precipitation was observed. EXAMPLES 8 AND 9
582.60 35.000
*A mixture containing 77 percent isobutane, 4 percent n-butane, and 19 percent propane by weight.
The drug (atropine in Example 8 and captopril in Example 9) and the phosphatidylcholine were weighed into a plastic coated glass bottle which was then sealed with a non-metering valve. The required quantity of n-butane was then pressure-filled into the sealed bottle to form a concentrate. The sealed bottle was then heated for 1 hour at 55°C in a water bath. The sealed bottle was then allowed to cool to room temperature and the remaining propellants were filled into the bottle.
EXAMPLE 8 The drug, atropine (base) , was solubilized within 1 hour in the concentrate and remained in solution when the remaining propellants were added.
EXAMPLE 9 The drug, captopril, was solubilized within one hour in the concentrate and remained in solution when the remaining propellants were added. EXAMPLES 10 AND 11 The following formulations were prepared:
Drug
Epikuron™ 200 n-Butane (20%) Ethanol (2.5%) Drivosol 32 (60%) Dimethylether (17.5%)
The formulations were prepared by weighing the drug (propranolol hydrochloride in Example 10 and diazepam in Example 11) , the phosphatidylcholine, and the ethanol into a glass vial, sealing the vial with a non-metering valve and pressure filling the required amount of n-butane into the sealed vial to form a concentrate. Each vial was then heated at 55°C for 2 hours in a water bath. The vials were allowed to cool to room temperature and the remaining propellants were filled into the vials.
The drugs both solubilized in the concentrate and remained in solution after cooling to room temperature and after remaining propellants were added.
In separate tests it was not possible to achieve solubilization of the drugs in the concentrate in absence of ethanol.

Claims

1. An aerosol formulation which contains substantially no dispersed phase, comprising: an aerosol propellant system comprising a propellant selected from n-butane, dimethylether and mixtures thereof; a glycerol phosphatide; and a drug, in which the drug is dissolved in the composition in an amount greater than could be achieved in the absence of the glycerol phosphatide.
2. A formulation according to Claim 1, wherein the propellant system further comprises a copropellant selected from isobutane, propane, and mixtures thereof.
3. A formulation according to Claim 1 or Claim 2 in which the glycerol phosphatide is selected from phosphatidylcholine, phosphatidylserine, diphosphatidylglycerol, phosphatidic acid, and mixtures thereof.
4. A formulation according to Claim 3 in which the glycerol phosphatide is phosphatidylcholine.
5. A formulation according to any preceding Claim in which the glycerol phosphatide is purified.
6. A formulation according to any preceding Claim in which the ratio of glycerol phosphatide to propellant is 0.01 to 20 : 100.
7. A formulation according to any preceding Claim in which the ratio of glycerol phosphatide to propellant is 0.01 to 10 : 100.
8. A formulation according to any preceding Claim in which the ratio of glycerol phosphatide to propellant is 0.01 to 3 : 100.
9. A formulation according to any preceding Claim in which the ratio of drug to glycerol phosphatide is 1 to 500 : 100.
10. A formulation according to any preceding Claim in which the ratio of drug to glycerol phosphatide is 1 to 30 : 100.
11. A formulation according to any preceding Claim in which the ratio of drug to glycerol phosphatide is 2 to 10: 100.
12. A formulation according to any preceding Claim which additionally comprises a cosolvent in an amount effective to enhance solubilization of the drug.
13. A formulation according to Claim 12 in which the cosolvent is ethanol.
14. A formulation according to any preceding Claim in which the drug is selected from beclomethasone dipropionate, betamethasone dipropionate, acetate, valerate and base thereof, albuterol, atropine base, and prednisolone.
15. A formulation according to any one of Claim 1 to 13 in which the drug is selected from diazepam, lorazepam, atropine, captopril, propranolol hydrochloride, hydrocortisone, fluocinolone acetonide, triamcinolone acetonide, xylometazoline hydrochloride, bitolterol mesylate, and lacicortone.
16. A formulation according to any preceding Claim containing less than 5% by weight of chlorofluorocarbons.
17. A formulation according to Claim 16 which is free of chlorofluorocarbons.
EP92920106A 1991-09-03 1992-08-28 Medicinal aerosol formulations Withdrawn EP0602181A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919118830A GB9118830D0 (en) 1991-09-03 1991-09-03 Medical aerosol formulations
GB9118830 1991-09-03
PCT/US1992/007379 WO1993004671A1 (en) 1991-09-03 1992-08-28 Medicinal aerosol formulations

Publications (1)

Publication Number Publication Date
EP0602181A1 true EP0602181A1 (en) 1994-06-22

Family

ID=10700844

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92920106A Withdrawn EP0602181A1 (en) 1991-09-03 1992-08-28 Medicinal aerosol formulations

Country Status (5)

Country Link
EP (1) EP0602181A1 (en)
AU (1) AU2573892A (en)
CA (1) CA2116862A1 (en)
GB (1) GB9118830D0 (en)
WO (1) WO1993004671A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203481A (en) 1990-10-18 1992-07-01 Minnesota Mining & Mfg FORMULATIONS.
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
DE19616573C2 (en) 1996-04-25 1999-03-04 Pari Gmbh Use of subcritical blowing agent mixtures and aerosols for the micronization of drugs with the help of dense gases
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
JP2001517689A (en) 1997-10-01 2001-10-09 フレミントン ファーマシューティカル コーポレイション Polar or non-polar buccal spray or capsule
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030185761A1 (en) 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6660715B2 (en) * 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
DE19911064A1 (en) * 1999-03-12 2000-09-14 Ig Spruehtechnik Gmbh MDIs with isobutane as propellant
DE10260882B4 (en) * 2002-12-24 2007-02-08 IG Sprühtechnik GmbH & Co. KG Metered aerosols with soy lecithin as a surface-active substance and its use
NZ523920A (en) 2003-01-31 2005-11-25 Fonterra Co Operative Group Methods for extracting lipids from diary products using a near critical phase fluid
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
BR112012030653B1 (en) * 2010-06-11 2021-10-13 Leo Pharma A/S TOPICAL AEROSOL COMPOSITION AND PRESSURIZED CONTAINER

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE632504A (en) * 1962-05-24
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
GB9001019D0 (en) * 1990-01-17 1990-03-14 Euro Celtique Sa Pharmaceutical aerosol
DE4003270A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg NEW SPEED GASES AND THEIR USE IN MEDICINE PREPARATIONS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9304671A1 *

Also Published As

Publication number Publication date
CA2116862A1 (en) 1993-03-18
GB9118830D0 (en) 1991-10-16
AU2573892A (en) 1993-04-05
WO1993004671A1 (en) 1993-03-18

Similar Documents

Publication Publication Date Title
JP2786493B2 (en) Pharmaceutical aerosol formulation
KR890004690B1 (en) Drug-containing chlorofluorocarbon aerosol propellent formulations
US5439670A (en) Medicinal aerosol formulations
US6352684B1 (en) CRC-free medicinal aerosol formulations of 1,1,1,2-tetrafluoroethane (134A) with polar adjuvant
US5681545A (en) Medicinal aerosol formulations
KR100375469B1 (en) Medicaments
EP0755247B1 (en) Hydrofluorocarbon propellant containing medicinal aerosols
AU658854B2 (en) Aerosol formulation comprising beclomethasone 17,21 dipropionate
EP0789557B1 (en) Propellant mixture for aerosol formulation
EP1306082B1 (en) Pressurized metered dose inhalers and pharmaceutical aerosol formulations
JP4672143B2 (en) Pharmaceutical aerosol formulation
ES2289832T3 (en) PHARMACEUTICAL AEROSOL COMPOSITION CONTAINING HFA 227 AND HFA 134A.
EP0602181A1 (en) Medicinal aerosol formulations
JPH10510829A (en) Aerosol formulation
PT96639B (en) PROCESS FOR PREPARING A PROPULSIVE COMPOSITION CONTAINING HYDRO-FLUORO-CARBONETES
KR0175164B1 (en) Aerosol drug formulations
NZ243056A (en) Aerosol formulation containing a medicament, tetrafluoroethane and isopropyl myristate
CA2303601A1 (en) Medicinal aerosol formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT SE

17Q First examination report despatched

Effective date: 19940929

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950210